
EnteroMedics
Total Raised
$81.47MInvestors Count
9Deal Terms
3Funding, Valuation & Revenue
9 Fundings
EnteroMedics has raised $81.47M over 9 rounds.
EnteroMedics's latest funding round was a IPO for $40M on November 14, 2007.
EnteroMedics's latest post-money valuation is from November 2007.
Sign up for a free demo to see EnteroMedics's valuations in November 2007 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
11/14/2007 | IPO | $40M | 2 | |||
10/5/2007 | Unattributed VC - VI | |||||
12/21/2006 | Unattributed VC - V | |||||
12/22/2005 | Unattributed VC - IV | |||||
12/14/2005 | Series B |
Date | 11/14/2007 | 10/5/2007 | 12/21/2006 | 12/22/2005 | 12/14/2005 |
|---|---|---|---|---|---|
Round | IPO | Unattributed VC - VI | Unattributed VC - V | Unattributed VC - IV | Series B |
Amount | $40M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 2 |
EnteroMedics Deal Terms
3 Deal Terms
EnteroMedics's deal structure is available for 3 funding rounds, including their IPO from November 14, 2007.
Round | IPO | Unattributed VC - V | Series B |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Unattributed VC - V | |||||||||||||||
Series B |
EnteroMedics Investors
9 Investors
EnteroMedics has 9 investors. Western Technology Investment invested in EnteroMedics's Unattributed VC - VI funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
9/23/2005 | 10/5/2007 | 2 Unattributed VC - III, Unattributed VC - VI (2007) | Debt & Specialty Finance | California | ||
Venture Capital | Massachusetts | |||||
Venture Capital | California | |||||
Venture Capital | California | |||||
Venture Capital | California |
First funding | 9/23/2005 | ||||
|---|---|---|---|---|---|
Last Funding | 10/5/2007 | ||||
Investor | |||||
Rounds | 2 Unattributed VC - III, Unattributed VC - VI (2007) | ||||
Board Seats | |||||
Type | Debt & Specialty Finance | Venture Capital | Venture Capital | Venture Capital | Venture Capital |
Location | California | Massachusetts | California | California | California |
EnteroMedics Acquisitions
2 Acquisitions
EnteroMedics acquired 2 companies. Their latest acquisition was ReShape Medical on October 03, 2017.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
10/3/2017 | Debt | $110.07M | Acquired | 2 | ||
5/23/2017 |
Date | 10/3/2017 | 5/23/2017 |
|---|---|---|
Investment Stage | Debt | |
Companies | ||
Valuation | ||
Total Funding | $110.07M | |
Note | Acquired | |
Sources | 2 |
Compare EnteroMedics to Competitors

Beta-O2 Technologies is a biomedical company that focuses on developing a proprietary implantable bioartificial pancreas for the treatment and potential cure of type 1 diabetes. The company's main product, the ßAir device, contains living cells that sense glucose levels and produce insulin and glucagon, aiming to maintain glycemic control without the need for insulin injections or glucose monitoring. The device is designed to provide immune-isolation of the implanted cells, which may eliminate the need for immunosuppressive therapy. It was founded in 1999 and is based in Rosh HaAyin, Israel.
Portaero, in stealth mode, is a medical devices firm, developing a device for the treatment of COPD (Chronic obstructive pulmonary disease).
Medical devices for the treatment of severe gastrointestinal disorders

Mobius Therapeutics specializes in the development and manufacturing of perioperative pharmaceuticals for the ophthalmology sector. The company offers FDA approved products that improve the preparation and delivery of mitomycin-c in surgeries, catering to the specific needs of the operating room. It is based in St. Louis, Missouri.

LinguaFlex is a medical device company focused on developing innovative technology for the treatment of obstructive sleep apnea. Their main offering is a patent-pending, minimally invasive device designed to prevent airway blockage by the tongue during sleep, which is currently under clinical investigation. The device is targeted towards individuals with moderate-to-severe obstructive sleep apnea who are seeking alternatives to traditional CPAP machines. It is based in Weston, Florida.

Accord BioMaterials specializes in home improvement and renovation products across various sectors including heating, cooling, and air quality management. The company offers a wide range of products such as heaters, air conditioners, humidifiers, air purifiers, and materials for home renovation and safety. These products cater to the needs of homeowners looking to enhance their living spaces with functional and aesthetic improvements. It was founded in 2008 and is based in Ann Arbor, Michigan.
Loading...

